logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Keros Therapeutics, Inc.


USPTO Granted Patents = 17


Trademarks = 4

Forward Citations = 31

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Jennifer Lachey (16 out of 21 patents)

silverMedal Jasbir S Seehra (16 out of 112 patents)

bronzeMedal Elissa Furutani (2 out of 2 patents)

4.  Henning Thøgersen (1 out of 7 patents)

5.  Catherine Anne Evans (1 out of 44 patents)

6.  Claudia Ordonez (1 out of 1 patent)

7.  Claire Tseng (1 out of 1 patent)

8.  Sarah Bethune (1 out of 1 patent)

9.  Krista Diaz (1 out of 1 patent)

10.  Christopher R Rovaldi (1 out of 1 patent)

11.  Jason O'NEILL (1 out of 1 patent)


17 patents:

1. 12582700 - ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF (2026-03-24),
2. 12522646 - ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF (2026-01-13),
3. 12508262 - Methods of using ALK2 inhibitors (2025-12-30),
4. 12458693 - Methods of treating iron overload with a BMP inhibitor (2025-11-04),
5. 12440539 - Methods of using activin receptor type IIB variants (2025-10-14),
6. 12404313 - GDNF fusion polypeptides and methods of use thereof (2025-09-02),
7. 12364737 - Activin receptor type IIA variants and methods of use thereof (2025-07-22),
8. 12350313 - Activin receptor type IIa variants and methods of use thereof (2025-07-08),
9. 12331124 - ALK2 antibodies and methods of use thereof (2025-06-17),
10. 12269858 - Activin receptor type IIB variants and methods of use thereof (2025-04-08),
11. 12071438 - Crystal forms of an ALK2 inhibitor (2024-08-27),
12. 11912750 - GDNF fusion polypeptides and methods of use thereof (2024-02-27),
13. 11884715 - Activin receptor type IIB variants and methods of use thereof (2024-01-30),
14. 11717558 - Nucleic acid molecules encoding activin receptor type IIA variants (2023-08-08),
15. 11484573 - Activin receptor type IIa variants and methods of use thereof (2022-11-01),
Company Overview
Keros Therapeutics, Inc. is a biotechnology company based in Lexington, MA, focused on developing innovative therapies for patients with rare diseases and serious conditions. The company specializes in advancing treatments that target the transforming growth factor-beta (TGF-β) superfamily, which plays a crucial role in various biological processes. Keros Therapeutics aims to address unmet medical needs through its proprietary drug development programs, leveraging cutting-edge research to improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

17 Patents

#40 in Lexington, MA

#1,150 in Massachusetts

#18,894 in US

#35,918 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Keros Therapeutics, Inc.

Forward Citations = 31

11 inventors:

goldMedal Jennifer Lachey (16 out of 21 patents)

silverMedal Jasbir S Seehra (16 out of 112 patents)

bronzeMedal Elissa Furutani (2 out of 2 patents)

4.  Henning Thøgersen (1 out of 7 patents)

5.  Catherine Anne Evans (1 out of 44 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Keros Therapeutics, Inc.. Retrieved from https://idiyas.com/company/keros-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…